Key facts
- It has raised $60.0M; the latest was Early Stage VC ($39.0M) in Feb 2026.
- Notable investors include Entrepreneurs First, Speedinvest, BlueYard Capital, EQT Life Sciences, Norrsken VC — 15 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 15 names
- ·Watchlist + deal alerts for Aerska
- ·The full record, as it builds
Funding rounds
No funding rounds for Aerska are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Aerska
Developer of RNA medicines designed to treat, delay, and prevent diseases of the brain. The company silences the genes that cause harm, aims to preserve minds, protect memories, and enable our loved ones to live healthy and long lives, and offers unprecedented potency, durability, and precision for hitting disease targets at their origin, intracellularly, enabling healthcare professionals to provide effective care and improve patient outcomes.
- Sector
- Healthcare
- HQ
- Wilmington, DE, United States
- Founded
- 2025
- Employees
- 21
- Website
- aerska.com/
- Ownership
- Privately Held (backing)
Aerska doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Aerska shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Aerska in its N-PORT filings yet. We sweep new filings monthly.